RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human primates following a single administration SOMERVILLE, Mass., Jan. 09, ...
SOMERVILLE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- SOMERVILLE, Mass., March 23, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in ...
Latest Financing Round Will Support Tessera’s Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera ...
In a recent study published in Cell, a research team led by LI Wei and ZHOU Qi from the Institute of Zoology of the Chinese Academy of Sciences has developed an innovative gene-writing technology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D. as Chief Medical and Development Officer, ...
Tessera Therapeutics is pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, with the aim to unlock broad new therapeutic frontiers. Our ...
The collaboration will utilize the Serotiny platform to engineer, analyze, score, and screen Multi-Domain Protein libraries aiming to identify and optimize Tessera’s novel programmable Gene Writer ...
In case you haven't heard, Tessera Therapeutics Inc. is working on techniques to write genes into the genome of patients. Tessera, which was developed in Flagship Pioneering Inc.'s Flagship Labs and ...
The technology has been developed by researchers from the Translational Synthetic Biology Laboratory at UPF led by Dr. Marc Güell. Find Cut-and-Transfer (FiCAT) is a tool capable of accurately writing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results